公开(公告)号：US20180292391A1

公开(公告)日：2018-10-11

申请号：US15900589

申请日：2018-02-20

Applicant: Genentech, Inc. ,  AIMM Therapeutics B.V.

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Eric J. BROWN ,  John Hiroshi MORISAKI ,  Wouter L.W. HAZENBOS ,  Sanjeev MARIATHASAN ,  Kimberly KAJIHARA ,  Yi XIA

IPC: G01N33/50 ,  G01N33/68 ,  C07K16/12

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

公开(公告)号：US20180037655A1

公开(公告)日：2018-02-08

申请号：US15790680

申请日：2017-10-23

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  C12Q1/68 ,  G01N33/574

CPC classification number: C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57407 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US20160168232A9

公开(公告)日：2016-06-16

申请号：US13786206

申请日：2013-03-05

Applicant: Genentech, Inc. ,  AIMM Therapeutics B.V.

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Eric J. BROWN ,  John Hiroshi MORISAKI ,  Wouter L.W. HAZENBOS ,  Sanjeev MARIATHASAN ,  Kimberly KAJIHARA ,  Yi XIA

IPC: C07K16/12

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

公开(公告)号：US20150376266A1

公开(公告)日：2015-12-31

申请号：US14728826

申请日：2015-06-02

Applicant: Genentech, Inc. ,  AIMM Therapeutics B.V.

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Eric J. BROWN ,  John Hiroshi MORISAKI ,  Wouter L.W. HAZENBOS ,  Sanjeev MARIATHASAN ,  Kimberly KAJIHARA ,  Yi XIA

IPC: C07K16/12

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

Abstract translation: 本发明提供能够特异性结合革兰氏阳性细菌的改进的结合化合物。 提供了完全人类的结合化合物，可在人类个体中实现治疗应用。